| | By Fraiser Kansteiner The fact that so many patients are clamoring for Trulicity and tirzepatide—approved in Type 2 diabetes this summer as Mounjaro—could prove to be a double-edged sword for Eli Lilly, whose executives on Tuesday warned of supply challenges ahead of a capacity-doubling manufacturing expansion planned for the end of 2023. |
|
|
|
By Nick Paul Taylor The dream of taming IL-2 keeps slipping further away. After seeing Bristol Myers Squibb and Nektar Therapeutics give up on their candidate, Sanofi has reported “lower than projected” efficacy data on its prospect and rethought its plans for the molecule. |
By Fraiser Kansteiner Oral versions of the common antibiotic amoxicillin—often used on the front lines of childhood bacterial infections—are running scarce in the U.S., as the Halloween season dovetails with a surge in pediatric respiratory syncytial virus (RSV) cases. |
By Max Bayer Lilly is exuding optimism as the race to develop a breakthrough Alzheimer's treatment hits the home stretch. The company is hoping to stay neck-and-neck with Eisai after the latter turned heads with its phase 3 lecanemab data. |
|
Tuesday, November 8, 2022 | 2pm ET / 11am PT Join this webinar to learn about the latest data-driven trends in strategy development, including the types of data and insights Med Tech companies are starting to use today, and more. Register now. 
|
|
By Zoey Becker Last quarter, Gilead Sciences said it was aiming to ramp up its oncology franchise. That goal played out nicely for the company in its latest earnings report, with third-quarter sales skyrocketing 79% year over year. Gilead aims to derive a third of its revenue from oncology products by 2030, the company announced in April. |
By Max Bayer A new STAT News investigation has found that Eisai's experimental Alzheimer's drug lecenemab may have contributed to a patient's death, according to documents obtained by the outlet. The Japanese pharma acknowledged the death but wouldn't divulge specific details citing patient privacy. |
By Fraiser Kansteiner AbbVie reported total third-quarter sales of $14.81 billion, up 5.4% operationally. Immunology continued its reign as the company’s top business, growing its revenues more than 16% to $7.651 billion. |
By Andrea Park During a call with investors on Thursday, CEO Mick Farrell reported that snags in the supply chain are beginning to smooth out, putting ResMed on track to ramp up production in the coming months. |
By Angus Liu Over a year after the FDA’s dreaded boxed warning addition and treatment line demotion, the JAK inhibitor class of inflammatory disease drugs has gotten its uses restricted by European regulators as well out of safety concerns. |
By Helen Floersh Researchers have designed a new molecule that increases serotonin signaling, with improvements in as little as two hours in mouse models of depression. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Wednesday, November 9, 2022 | 2pm ET / 11am PT This webinar is one of the first opportunities for sales leaders, operations professionals, and other stakeholders in the medical device industry to see the native Salesforce inventory platform. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
